New Diagnostic and Molecular Characteristics of Malignant Mesothelioma

Davidson, Ben

doi:10.1080/01913120802454298

Cited by 18 publications

(4 citation statements)

References 196 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MPM is a very rare disease, especially in women where markers used to diagnose MPM may be also elevated in cases with cancer of the ovaries 33 . Our prediction for female candidates with tissue samples waiting for histopathological diagnostic workup resulted in 3% false-positive decisions and 75% true-positive decisions for a probability of 30% for mesothelin alone.…”

Section: Discussionmentioning

confidence: 99%

Biomarkers for Predicting Malignant Pleural Mesothelioma in a Mexican Population

et al. 2018

View full text Add to dashboard Cite

Background: Diagnosis of malignant pleural mesothelioma (MPM) remains a challenge, especially when resources in pathology are limited. The study aimed to evaluate cost-effective tumor markers to predict the probability of MPM in plasma samples in order to accelerate the diagnostic workup of the tissue of potential cases.Methods: We conducted a case-control study stratified by gender, which included 75 incident cases with MPM from three Mexican hospitals and 240 controls frequency-matched by age and year of blood drawing. Plasma samples were obtained to determine mesothelin, calretinin, and thrombomodulin using enzyme-linked immunosorbent assays (ELISAs). We estimated the performance of the markers based on the area under the curve (AUC) and predicted the probability of an MPM diagnosis of a potential case based on the marker concentrations.Results: Mesothelin and calretinin, but not thrombomodulin were significant predictors of a diagnosis of MPM with AUCs of 0.90 (95% CI: 0.85-0.95), 0.88 (95% CI: 0.82-0.94), and 0.51 (95% CI: 0.41-0.61) in males, respectively. For MPM diagnosis in men we estimated a true positive rate of 0.79 and a false positive rate of 0.11 for mesothelin. The corresponding figures for calretinin were 0.81 and 0.18, and for both markers combined 0.84 and 0.11, respectively.Conclusions: We developed prediction models based on plasma concentrations of mesothelin and calretinin to estimate the probability of an MPM diagnosis. Both markers showed a good performance and could be used to accelerate the diagnostic workup of tissue samples in Mexico.

show abstract

Section: Discussionmentioning

confidence: 99%

Biomarkers for Predicting Malignant Pleural Mesothelioma in a Mexican Population

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Furthermore, the effective combinatorial therapeutic regimes involving RNA interference and chemotherapeutics for combating survivin in mesothelioma are in consideration . The regulatory role of survivin in mesothelioma was prominently mediated via upregulation of IAP family members notably IAP1, IAP2, neuronal apoptosis inhibitory protein (NAIP) and livin, further leading to downregulation of caspase 3, caspase 7, and caspase 9 apoptotic signaling mechanisms …”

Section: Survivin Signaling Mechanisms In Clinical Cancersmentioning

confidence: 99%

Survivin Signaling in Clinical Oncology: A Multifaceted Dragon

Kanwar

Kamalapuram

Kanwar

2012

Medicinal Research Reviews

View full text Add to dashboard Cite

Survivin is an inhibitor of apoptosis protein (IAP) family member preferentially expressed in a myriad of clinical cancers. The complex functional mechanism and regulatory roles of survivin in cell division and cell death has hindered current therapeutic regimes from decoding its diagnostic, prognostic, and therapeutic significance in the area of translational oncology. Pharmacological modulation of survivin was tagged with its evolving functional complexity associated with various cell-signaling cascades including PI3K/AKT, mammalian target of rapamycin (mTOR), extracellular signal-regulated kinases (ERK), mitogen-activated protein kinases (MAPK), signal transducer and activator of transcription (STAT), hypoxia-inducible factor-1α (HIF-1α), heat-shock protein 90 (HSP90), p53, B-cell lymphoma 2 (Bcl2), epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF) etc. The present review provides a multifaceted role of survivin and its mechanistic action in an array of clinical cancers. Furthermore, the utilization of novel nanotechnology-based drug delivery systems for target-specific hurling of tumors enabling contemporaneous detection, treatment, and therapeutic imaging in cancer therapy are discussed.

show abstract

“…In up to 80% of cases, exposure to asbestos has been documented. 1 The global number of MPM patients is expected to rise due to worldwide use of asbestos until recently and the long latency period of this fatal malignancy. 2,3 Advanced tumor stage at diagnosis with extended local spread to surrounding structures and resistance to various treatment modalities are characteristic for MPM and result in median patient survival of only 9 to 12 months.…”

mentioning

confidence: 99%